Samit Hirawat, Bristol Myers Squibb CMO (Bristol Myers)
Bristol Myers celebrates a big win with FDA approval of $13B cardio drug mavacamten
After getting hit with an FDA delay back in November, Bristol Myers Squibb is finally celebrating a win for mavacamten, the centerpiece of the company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
